Allosteric modulators for
human health
About us
Addex Corporate Presentation
Overview
Our people
Executive Officers
Non-Executive Directors
Contact
Privacy Policy
Careers
Pipeline
Clinical and Pre-Clinical Pipeline
Research And Development
Technology
Allosteric modulation
Publications
Partners & collaboration
Investors
Addex Corporate Presentation
Stock Data
Press releases
Ad hoc announcements (Art. 53 L.R)
Events
Financial Reports
Analyst Reports
General Meetings
SEC / SIX Filings
Guide to US ADSS for Six Shareholders
Register for email news
Corporate Governance
Contact
Media
Press releases
Contact
Press releases
All Years
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
Please select year
04.29
2024
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
04.19
2024
Addex to Present at the Swiss Biotech Day 2024
04.18
2024
Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
04.11
2024
Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
04.02
2024
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
03.14
2024
Addex to Present at the Bio-Europe Spring 2024 Conference
01.31
2024
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
01.09
2024
Addex to Present at the Swiss Equities Baader Conference
01.05
2024
Addex to Present at Biotech Showcase™ 2024
12.20
2023
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
Next
Back